Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Price ‘Negotiation’ Process Could Enable National Value Framework – CMS’ Blum

Executive Summary

Centers for Medicare and Medicaid Services chief operating officer Jonathan Blum discusses implementation of an unprecedented new price setting program and how it might impact value-based pricing more broadly in a recent interview with Health Affairs.

You may also be interested in...



US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin

The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview the US Inflation Reduction Act, telehealth, interoperability of healthcare data, and Mark Cuban’s pharma venture.

US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin

The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview with Scrip the US Inflation Reduction Act, telehealth,  interoperability of healthcare data, and Mark Cuban’s pharma venture.

Medicare Drug Price Control Group Formed At CMS: How Will Stakeholders Interact?

As the Centers for Medicare and Medicaid Services begins the process of building new price negotiation and inflation rebate programs within Medicare, stakeholders are watching to see how transparent the process will be and how much outside input the agency will seek.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS147066

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel